ADIL - Cash Flow Statement - Adial Pharmaceuticals, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015
OPERATING CASH FLOW
Net Income	(13.2)	(7.0)	(12.7)	(19.4)	(10.9)	(8.6)	(11.6)	(1.1)	(0.4)	(0.8)
Depreciation & Amortization	565	564	60.5 K	55.1 K	564	565	563	565	565	565
Deferred Income Tax	0	(1.9)	502	94.1 K	(1.6)	0	3.5	0	0	0
Stock Based Compensation	0.8	1.8	3.4	4.2	2.0	1.6	5.4	0.2	0.2	0.3
Other Operating Activities	5.1	1.1	(0.5)	1.8	1.6	0.4	1.1	0.1	7	1.09 K
Change in Working Capital	0.4	(0.8)	(1.4)	1.5	1.2	0.2	(0.8)	0.3	8.32 K	0.1
Cash From Operations	(6.9)	(6.8)	(11.2)	(11.9)	(7.6)	(6.3)	(2.5)	(0.5)	(0.3)	(0.5)
INVESTING CASH FLOW
Capital Expenditures	0	6.8	0	64.6 K	0	0	0	0	0	0
Other Items	0	(5.3)	0	30.6 K	(0.3)	0	0	35.1 K	0	0
Cash From Investing Activities	0	1.5	0	34 K	(0.3)	0	0	35.1 K	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	1.66 K	0	0	0	0	0	0	0	0
Total Debt Repaid	0	0	0	0	0	0	75 K	0.3	0.2	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Other Financing Activities	3.8	0	1.86 K	1.9	0.5	1.1	0.2	0	0	0
Cash From Financing Activities	7.8	4.1	9.1	13.6	5.6	9.2	6.3	0.4	0.2	0
CHANGE IN CASH
Net Change In Cash	0.9	(1.2)	(2.1)	1.7	(2.4)	2.9	3.9	69.7 K	74.4 K	(0.5)
FREE CASH FLOW
Free Cash Flow	(6.9)	0	(11.2)	(12.0)	(7.6)	(6.3)	(2.5)	(0.5)	(0.3)	(0.5)

Free